NeoCart Tissue Implant Superior to Microfracture (Biloine Young @ OTW)
The regenerative medicine company Histogenics Corporation received encouraging news in an article in the Journal of Bone and Joint Surgery reporting the two-year results of a Phase 2 clinical trial of its product NeoCart Autologous Cartilage Tissue Implant (ACTI). The implant is designed for patients with grade II chondral injury to the femur (the cartilage in the knee).
NeoCart is an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the repair of full thickness cartilage lesions...
